Medical Affairs Reputations: Type 2 Diabetes Mellitus [Injectables] (EU5) 2018

Close rivalries among European medical affairs teams for leading injectable type 2 diabetes mellitus therapies. Will your team come out on top?

In Europe, one medical affairs team for a leading injectable therapy for type 2 diabetes mellitus leads the way in terms of interaction frequency and overall quality of interactions, but only 1 point separates teams in spots 2-4. Can other teams close the gap? 150 diabetologists and primary care physicians from the EU5 markets (France, Germany, Italy, Spain and the UK) provide insights on several medical affairs teams, and opinions are mixed. Will targeting improvements in certain areas be enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: Type 2 Diabetes Mellitus [Injectables] [2018]. This report, which covers 12 major injectable therapies in the type 2 diabetes market from Sanofi, Eli Lilly, Novo Nordisk, and GlaxoSmithKline, including Abasaglar, Eperzan, Humalog, Lantus, Lyxumia, NovoRapid, Ryzodeg, Toujeo, Tresiba, Trulicity, Victoza and Xultophy, provides handy graphs and charts that show at a glance how each team is performing across 12 key medical affairs activities, and where they need to improve:

• How diabetologists and primary care physicians rate your team overall, and on 12 key medical affairs services.
• Which medical affairs services are most important.
• How, and how often diabetologists and primary care physicians want to meet with your team.
• What you can do to improve your medical affairs services.

That’s actionable information you can use to turn your team into one that doctors rely on.

Interested in the US market? Click here to see the US Edition.

Request sample pages

• All to play for at the top of the table. One team leads the way, but only 1 point separates teams in spots 2-4, suggesting that there’s still room to move up the table if the right tactics are adopted. But what areas will make all the difference?
• Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions, with nearly all teams tasked with improving in this area.
• Good levels of activity. In the past six months, 6 of 12 teams interacted with more than 70 percent of doctors surveyed, and the least active teams saw 23 percent of them, suggesting healthy levels of physician interaction.
• In person or via digital channels? The report reveals how physicians want to interact with type 2 diabetes medical affairs teams. Use this information to refine your medical affairs strategy.

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

• FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
• FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.